$HIMS 20260529 20.5 PUT$ I am bullish in Hims. Hims & Hers Health (HIMS) is heavily expanding its GLP-1 weight-loss offerings and platform, recently bringing access to generic semaglutide to Canada. To fund international growth and AI investments, the company priced an upsized $350 million convertible note offering.
Additionally, insider buying has surged, signaling strong corporate confidence. Key Corporate & Platform UpdatesGLP-1 Expansion: The telehealth platform expanded its weight-loss footprint internationally by launching generic semaglutide in Canada. Financial Moves: Prices for an upsized $350 million convertible senior notes offering were finalized to fuel international growth and accelerate AI-driven platform investments.
Platform Reach: Hims & Hers expanded its integrated health access and added eight new health and wellness partners for active subscribers.
Market & Insider ActivityInsider Buying: Lead Independent Director David Wells purchased additional shares, joining other executives in making notable insider investments to back the weight-loss drug pivot.
Stock Performance: Following recent price action, HIMS is up roughly 19% year-to-date and 50% over the last 12-month period
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
